Key result
Androgen deprivation therapy increased the risk of heart failure by approximately 30% in patients with prostate cancer.
Why the study?
The relationship between androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer required systematic investigation.
Does androgen deprivation therapy increase the risk of heart failure in patients with prostate cancer?
Meta-Analysis (n=189,045)
Does androgen deprivation therapy increase the risk of heart failure in patients with prostate cancer?
Androgen deprivation therapy is associated with a 30% increased risk of heart failure in patients with prostate cancer, highlighting the need for cardiovascular monitoring in this population.
Answers are grounded in this paper and cite their sources.
ADT may warrant closer HF monitoring in prostate cancer; leaves open causal confirmation via RCTs.
BACKGROUND & AIM: We aimed in this study to investigate the relationship between Androgen Deprivation Therapy (ADT) use and the risk of heart failure in patients with prostate cancer. In this research, the negative or positive effects of ADT in the development of cardiovascular diseases or its exacerbation in people with prostate cancer have been investigated. MATERIALS AND METHODS: For this research, we reviewed articles from PubMed, Scopus, and Google Scholar databases until February 2024. We extracted and screened titles, abstracts, and full texts of related articles. The quality of studies was assessed and extracted and analyzed data. RESULT: A total of 9 studies comprising 189,045 patients were included in the meta-analysis, examining the association between androgen deprivation therapy (ADT) and heart failure. The overall pooled hazard ratio (HR) was 1.299 (95% CI: 1.003-1.595), indicating a significantly increased risk of heart failure with ADT. Subgroup analyses revealed that the risk was stronger in Asian populations (pooled HR = 1.545, 95% CI: 1.180-1.910) compared to North American populations (pooled HR = 0.779, 95% CI: 0.421-1.138). CONCLUSIONS: ADT has a significant relationship with cardiovascular disease. According to the analysis, ADT has increased the risk of heart failure in people with prostate cancer by 30%.
No takes yet. Share an insight, caveat, or question.
Khorram et al. (2024) conducted a meta-analysis in Prostate cancer (n=189,045). Androgen Deprivation Therapy (ADT) vs. No Androgen Deprivation Therapy was evaluated on Risk of heart failure (HR 1.299, 95% CI 1.003-1.595). Androgen deprivation therapy increased the risk of heart failure by approximately 30% in patients with prostate cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: